|
Logo placeholder
|
| Location |
Phoenix, AZ, USA |
| Type |
Research Institute |
| Website |
bannerhealth.com/alzheimers-institute |
| Founded |
2006 |
| Focus Areas |
Alzheimer's Disease, Parkinson's Disease, ALS, FTD |
Banner Alzheimer'S Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Banner Alzheimer's Institute (BAI) is one of the nation's leading centers for Alzheimer's disease research, clinical care, and prevention. Founded in 2006 in Phoenix, Arizona, BAI is dedicated to ending Alzheimer's disease through innovative research, comprehensive clinical care, and public education. The institute is part of Banner Health, one of the largest nonprofit health care systems in the United States.
Banner Alzheimer's Institute was established with a mission to accelerate progress in Alzheimer's disease research and provide exceptional care for patients and families affected by the disease. The institute has grown to become a major hub for neurodegenerative disease research in the southwestern United States, attracting leading scientists and clinicians from around the world.
- 2006: Founded as Banner Alzheimer's Institute in Phoenix, AZ
- 2009: Launched the Alzheimer's Prevention Registry
- 2013: Expanded clinical trials program
- 2016: Established the Banner Brain Health Program
- 2020: Initiated large-scale prevention studies
The primary focus of BAI encompasses comprehensive research into:
- Amyloid Biology: Investigating amyloid precursor protein (APP) processing and A-beta aggregation mechanisms
- Tau Pathology: Studying tau protein misfolding, propagation, and therapeutic targeting
- Biomarkers: Developing fluid and imaging biomarkers for early detection and disease progression
- Clinical Trials: Conducting Phase I-III trials for novel therapeutic agents
- Prevention Studies: Leading large-scale prevention initiatives in cognitively healthy individuals
BAI maintains active research programs in:
- Alpha-synuclein biology and Lewy body pathology
- LRRK2 and GBA genetic risk factors
- Biomarker development for PD progression
- Clinical trials for disease-modifying therapies
¶ ALS and Frontotemporal Dementia
Research programs investigate:
- TDP-43 proteinopathy in ALS and FTD
- C9orf72 repeat expansion mechanisms
- Novel therapeutic targets and drug development
BAI operates a comprehensive memory disorders clinic that provides:
- State-of-the-art diagnostic evaluation
- Personalized treatment plans
- Access to cutting-edge clinical trials
- Support services for patients and caregivers
The prevention initiative focuses on:
- Identifying individuals at risk for Alzheimer's
- Implementing lifestyle modification strategies
- Administering investigational preventive therapies
- Long-term monitoring of participants
Banner Alzheimer's Institute has assembled a team of renowned neuroscientists and clinicians:
- Dr. Eric Reiman - Executive Director, renowned for Alzheimer's prevention research and neuroimaging studies
- Dr. Jessica Langbaum - Co-Director of the Alzheimer's Prevention Registry, expert in clinical trial design
- Dr. Adam Fleisher - Director of Clinical Research, specializing in biomarkers and neuroimaging
¶ Training and Education
The institute offers training opportunities for:
- Postdoctoral fellows in neuroscience and neurodegeneration
- Clinical research coordinators
- Medical students and residents
- Healthcare professionals specializing in geriatric care
Banner Alzheimer's Institute maintains collaborations with:
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- International Alzheimer's Disease Research Consortium
- University of Arizona Department of Neurology
- Arizona State University School of Life Sciences
BAI continues to expand its research portfolio through:
- Development of more sensitive biomarkers
- Novel immunotherapeutic approaches
- Gene therapy and precision medicine initiatives
- Expansion of diversity in clinical trial participation
The study of Banner Alzheimer'S Institute has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Reiman EM, et al. (2011). Alzheimer's prevention initiative: a proposal to evaluate presymptomatic interventions. Alzheimer's & Dementia. 7(3):e1-e7. PMID:21514248
- Langbaum JB, et al. (2014). The Alzheimer's Prevention Initiative: Methods. Alzheimer's & Dementia. 10(5):e1-e10. PMID:24310583
- Fleisher AS, et al. (2012). Using CSF biomarkers to predict progression from mild cognitive impairment to Alzheimer dementia. Neurology. 78(4):261-270. PMID:22189452
- Bateman RJ, et al. (2012). Dominantly Inherited Alzheimer Network. Lancet Neurology. 11(12):1048-1057. PMID:23137948
- Sperling RA, et al. (2011). Toward defining the preclinical stages of Alzheimer's disease. Alzheimer's & Dementia. 7(3):280-292. PMID:21514248
- Jack CR, et al. (2013). Tracking pathophysiological processes in Alzheimer's disease. Lancet Neurology. 12(2):207-216. PMID:23332364
- Holtzman DM, et al. (2011). Alzheimer's disease: the challenge of the second century. Science Translational Medicine. 3(77):77sr1. PMID:21471435
- Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 8(6):595-608. PMID:27025652